TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05705908

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot Foot Bath 1
Description: * Hot foot bath device has a built-in heater (max. 44°C),~* Hot foot bath device has anti-slip base, vibration and 2 rotating massage rollers, digital display/control panel and timer (20-60 minutes).~* It is filled with water at 40 degrees so that it passes the ankle of the patient by 20 cm (4 liters of water).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot Foot Bath 2
Description: * Hot foot bath device has a built-in heater (max. 44°C),~* Hot foot bath device has anti-slip base, vibration and 2 rotating massage rollers, digital display/control panel and timer (20-60 minutes).~* It is filled with water at 40 degrees so that it passes the ankle of the patient by 20 cm (4 liters of water).~* 3 drops of lavender essential oil were dripped in the water
Study: NCT06359483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal Frequency Manipulation
Description: The intervention involves altering meal frequency among participants. One group consumes three standardized meals per day, while the other consumes eight smaller, more frequent meals. Meals are designed to meet nutritional needs and adhere to dietary guidelines. The aim is to assess the impact of meal frequency on bone remodeling by measuring the blood biomarker P1NP at various points during the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal Frequency Manipulation
Description: The intervention involves altering meal frequency among participants. One group consumes three standardized meals per day, while the other consumes eight smaller, more frequent meals. Meals are designed to meet nutritional needs and adhere to dietary guidelines. The aim is to assess the impact of meal frequency on bone remodeling by measuring the blood biomarker P1NP at various points during the study.
Study: NCT05248217

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: healthcare workers
Description: healthcare
Study: NCT04838366

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate loading
Description: study group will be intervened with carbohydrate loading as the protocol made by ERAS(Li et al., 2021). Surgical patients will be asked to drink a beverage containing 100 grams carbohydrate the night before surgery. On the day of surgery, patients will drink a beverage containing 50 grams carbohydrate 2 hours before surgery under the supervision of research team member. We will provide glucose-D (Dabur Nepal Private Limited, Bara, Nepal, (Regd No.: 3506/045/046, DFTQC No.: 01-33-55-03-218).
Study: NCT05381025

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kava (Piper methysticum) extract
Description: Each dose (3 capsules) contains kavalactones (225 mg) and silicified microcrystalline cellulose.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kava (Piper methysticum) extract
Description: Each dose (3 capsules) contains kavalactones (225 mg) and silicified microcrystalline cellulose.
Study: NCT05695456

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: personalized exclusion diet based on CLE
Description: personalized exclusion diet based on CLE

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: personalized exclusion diet based on CLE
Description: personalized exclusion diet based on CLE

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: empiric exclusion diet
Description: exclusion diet with milk or gluten-containing grains
Study: NCT05833503

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative Couple Treatment for Addiction (ICT-A)
Description: Couple-based intervention called Integrative Couple Treatment for Addiction (ICT-A).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment individual as usually offered
Description: Individual-based treatment as usually offer by the specialized centres in addiction.
Study: NCT05224492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulforaphane
Description: 40 mg of Sulforaphane powder once daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05395845

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: platelets rich plasma
Description: local ingection of platelets rich plasma
Study: NCT06202950

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Applying yoga for one hour a week for eight weeks to an adolescent with type 1 diabetes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: Applying mindfulness for one hour a week for eight weeks to an adolescent with type 1 diabetes
Study: NCT04928326

Intervention type: DIAGNOSTIC_TEST
Intervention: CorWatch
Description: Non-invasive wearable monitor for the assessment of central venous pressure
Study: NCT05862025

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Echocardiography evaluation
Description: Patients will undergo mandatory transthoracic echocardiography during assessment of Staphylococcus aureus bacteremia.~Later, they will also undergo mandatory transesophageal echocardiography.~Both test will be performed during the first 14 days from bacteremia onset.
Study: NCT05626036

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arthrex Tightrope
Description: High-tensile strength suture syndesmosis repair
Study: NCT05864417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen Color tone 2.0
Description: Participants will topically apply sunscreen color tone 2.0.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen Color tone 3.0
Description: Participants will topically apply sunscreen color tone 3.0.
Study: NCT06457789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-AraG PET imaging
Description: Patients will receive a static whole-body PET scan following a \[18F\]F-AraG injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [89Zr]Zr-Df-Crefmirlimab PET imaging
Description: Patients will receive a static whole-body PET scan following a \[89Zr\]Zr-Df-Crefmirlimab injection.
Study: NCT05662098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: All participants will receive an individualized PK hydroxyurea assessment. Participants for whom the PK-process successfully generates a dose in the predicted treatment range of 15-35 mg/kg/day, will start on that personalized dose. Participants for whom the process does not generate a starting hydroxyurea dose in the predicted treatment range, due to potential pitfalls in lab draws, serum storage, sample processing, or hydroxyurea analysis, will start at a default dose of 20.0 ± 2.5 mg/kg/day. For all participants, the hydroxyurea dose will be adjusted as needed based on blood counts to establish the optimal dose. Where necessary, a weekly dosing average will be determined, so that treatment can occur solely with locally available and affordable 500mg hydroxyurea capsules.
Study: NCT05626036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synthes Fibulink
Description: High-tensile strength suture syndesmosis repair
Study: NCT05402527

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Fish nutrients
Description: Intake of fish protein, omega-3 fatty acids, and vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Fish nutrients
Description: Intake of fish protein, omega-3 fatty acids, and vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Fish nutrients
Description: Intake of fish protein, omega-3 fatty acids, and vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Fish nutrients
Description: Intake of fish protein, omega-3 fatty acids, and vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Fish nutrients
Description: Intake of fish protein, omega-3 fatty acids, and vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Fish nutrients
Description: Intake of fish protein, omega-3 fatty acids, and vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Whey protein
Description: Intake of whey protein

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Whey protein
Description: Intake of whey protein

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Whey protein
Description: Intake of whey protein

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Whey protein
Description: Intake of whey protein

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Whey protein
Description: Intake of whey protein
Study: NCT04842318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR for 6 cycles +R for 8 cycles
Description: The patients will be given Bendamustine (90mg/m2 d1,2, every 28 days for total 6 courses) combined with Rituximab (375mg/m2 d0, every 28 days for total 6 courses) followed by Rituximab (375mg/m2 d1, every 3 months for total 8 courses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RCHOP for 6 cycles +R for 8 cycles
Description: The patients will be given RCHOP (Rituximab 375mg/m2 ivgtt, D0, Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1, Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses) followed by Rituximab (375mg/m2 d1, every 3 months for total 8 courses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R2 for 6 cycles + R2 maintenance
Description: The patients will be given Lenalidomide (25mg/d, po, D1-10, every 21 days for total 6 courses) combined with Rituximab (375mg/m2 d0, every 21 days for total 6 courses) followed by Lenalidomide (25mg/d, po, D1-10, every 28 days for total 6 courses) combined with Rituximab (375mg/m2 d1, every 3 months for total 8 courses)
Study: NCT04739202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab + Ipatasertib
Description: Atezolizumab IV (1200 mg on day 1 of each 21-day cycle) and Ipatasertib PO (400 mg per day continuously, starting on cycle 1 day 1). Treatment given until disease progression or unacceptable toxicity.
Study: NCT05402527

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Whey protein
Description: Intake of whey protein

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Maltodextrin
Description: Intake of maltodextrin
Study: NCT05799040

Intervention type: DEVICE
Intervention: Self-developed pulmonary lobar ventilation detector
Description: The participants would evaluated by the self-developed pulmonary lobar ventilation detector.

Intervention type: DEVICE
Intervention: Chartis detection system
Description: The participants would evaluated by the Chartis detection system.
Study: NCT04739202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab + Bevacizumab
Description: Atezolizumab IV (1200 mg on day 1 of each 21-day cycle) and Bevacizumab IV (15 mg/kg on day 1 of each 21-day cycle). Treatment given until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab + Bevacizumab
Description: Atezolizumab IV (1200 mg on day 1 of each 21-day cycle) and Bevacizumab IV (15 mg/kg on day 1 of each 21-day cycle). Treatment given until disease progression or unacceptable toxicity.
Study: NCT05038085

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: progressive muscle relaxation exercise
Description: 36-37 with pregnant women in the experimental group. There will be two online interviews starting from week one. Before the first interview, the PMRE video will be sent to the women, explained by the researcher. In the first meeting, basic information about postpartum depression and what to do to prevent postpartum depression and its treatment will be explained. The women will then be asked to describe the PKGE. Relaxation Exercises CD Audio Recordings belonging to the Turkish Psychological Association will be sent to women, and they will be asked to perform PMRE at least 3 days a week until delivery, accompanied by the instructions on the CD. In the second meeting; maternal attachment will be explained. In this interview, women will be asked to continue to do PMRE at least 3 days a week from the day they feel ready, starting at the latest 1 week after delivery.
Study: NCT05428358

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Preoperative MRI
Description: Preoperative MRI performed between outpatient visit at the surgical clinic and scheduled date of resection
Study: NCT04846400

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ssNPA
Description: The ssNPA is a self-supporting nasopharyngeal airway, a stent that is a non-surgical alternative to treat severe OSA
Study: NCT05377749

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FACT
Description: Families Addressing Cancer Together (FACT) is a web-based intervention that provides tailored communication support for parents with cancer.
Study: NCT05759689

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: Resource Energy
Description: Carbohydrate Supplement
Study: NCT05950672

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAT Intervention Group
Description: The experimental group will take part in the CAT intervention after baseline assessments. All cat-training methods will be positive reinforcement based, using owner-approved food, toys and social reinforcers (e.g. petting).
Study: NCT06225401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simcapture PRE
Description: Practice with the SimCapture for Skills interface before the traditional teaching with the teacher in the classroom

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simcapture POST
Description: Practice with the SimCapture for Skills interface after the traditional teaching with the teacher in the classroom
Study: NCT05759689

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Supplement: Resource Energy
Description: Carbohydrate Supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: Calogen
Description: Polyunsaturated liquid fat supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Supplement: Calogen
Description: Polyunsaturated liquid fat supplement
Study: NCT06538922

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single Session Family Intervention
Description: A health coach will deliver a 2-hour single-session consultation to support parent-teen dyadis in applying evidence-based family skills in daily life. Participants will then practice daily on their own for the next 7 days.
Study: NCT05590728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apramycin (EBL-1003)
Description: A mono-substituted 2-deoxystreptamine comprising a unique bicyclic octadiose moiety. It is a crystalline free base of the amoniglycoside apramycin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apramycin (EBL-1003)
Description: A mono-substituted 2-deoxystreptamine comprising a unique bicyclic octadiose moiety. It is a crystalline free base of the amoniglycoside apramycin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apramycin (EBL-1003)
Description: A mono-substituted 2-deoxystreptamine comprising a unique bicyclic octadiose moiety. It is a crystalline free base of the amoniglycoside apramycin.
Study: NCT05000593

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: normal saline
Description: Intra-articular injection of normal saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cord Blood Mononuclear Cells (UCB-MNCs)
Description: Intra-articular injection of Cord Blood Mononuclear Cells (UCB-MNCs)
Study: NCT04853394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MASLIHAT
Description: peer educator intervention
Study: NCT05590728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apramycin (EBL-1003)
Description: A mono-substituted 2-deoxystreptamine comprising a unique bicyclic octadiose moiety. It is a crystalline free base of the amoniglycoside apramycin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apramycin (EBL-1003)
Description: A mono-substituted 2-deoxystreptamine comprising a unique bicyclic octadiose moiety. It is a crystalline free base of the amoniglycoside apramycin.
Study: NCT04853394

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: TANSIHAT
Description: health education intervention
Study: NCT05663541

Intervention type: DIAGNOSTIC_TEST
Intervention: Lower extremity position test
Description: Assessing proprioception of the lower extremity of individuals multiple sclerosis
Study: NCT05551273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selgantolimod
Description: 1.5 mg tablet
Study: NCT06523894

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Adapted to tumor volume BC SBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Adapted to tumor volume BC SBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Adapted to tumor volume BC SBRT
Study: NCT06577597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3923868
Description: Participants will receive single dose of GSK3923868.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive single dose of Placebo.
Study: NCT05172726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tapinarof cream, 1%
Description: applied topically once daily
Study: NCT05841875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: C reactive protein algorithm
Description: Antibiotic therapy discontinuation will be encouraged under the following conditions:~If the peak CRP is below 100 mg/L: Consider stopping antibiotics when CRP falls below 35 mg/L, with a minimum treatment duration of 3 days.~If the peak CRP is above 100 mg/L or the patient meets criteria for sepsis or septic shock: Consider stopping antibiotics when CRP has decreased by 50%, after a minimum of 5 days.~If the patient does not meet the CRP criteria: Antibiotic discontinuation will be recommended after 5-7 days, provided there is clinical improvement.~Before discontinuing antibiotic therapy, physicians should confirm that the patient is clinically improving, with no signs of a persistent infectious focus. Additionally, they will be encouraged to verify that the Sequential Organ Failure Assessment (SOFA) score is stable or decreasing. These factors will assist in determining the appropriateness of stopping antibiotics.
Study: NCT06654440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A2102 for injection
Description: SHR-A2102 for injection
Study: NCT05919511

Intervention type: OTHER
Intervention: Non-Interventional
Description: This is an observational study
Study: NCT05233033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KT-413
Description: KT-413 will be supplied as 10mg/mL concentration frozen solution to be administered intravenously per the protocol defined dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KT-413
Description: KT-413 will be supplied as 10mg/mL concentration frozen solution to be administered intravenously per the protocol defined dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KT-413
Description: KT-413 will be supplied as 10mg/mL concentration frozen solution to be administered intravenously per the protocol defined dose level.
Study: NCT06625905

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound imaging
Description: Both groups of participants-those with myofascial and/or musculoskeletal pain and those without musculoskeletal alterations-will undergo a standardized intervention focused on the application of vibratory stimuli, alongside real-time ultrasound imaging. Vibratory stimuli will be applied directly to the region of interest, specifically over the identified MTrP in participants with active myofascial pain. In participants without musculoskeletal alterations, the stimuli will be applied either over a latent MTrP or in a randomly selected area of the gastrocnemius medialis muscle, ensuring a consistent methodology across both groups. Simultaneously, real-time ultrasound imaging will be performed to capture detailed images of the muscle tissue during the application of vibratory stimuli. Imaging will be conducted in two planes (longitudinally and transversely).

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound imaging
Description: Both groups of participants-those with myofascial and/or musculoskeletal pain and those without musculoskeletal alterations-will undergo a standardized intervention focused on the application of vibratory stimuli, alongside real-time ultrasound imaging. Vibratory stimuli will be applied directly to the region of interest, specifically over the identified MTrP in participants with active myofascial pain. In participants without musculoskeletal alterations, the stimuli will be applied either over a latent MTrP or in a randomly selected area of the gastrocnemius medialis muscle, ensuring a consistent methodology across both groups. Simultaneously, real-time ultrasound imaging will be performed to capture detailed images of the muscle tissue during the application of vibratory stimuli. Imaging will be conducted in two planes (longitudinally and transversely).
Study: NCT06720857

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Identification of a risk stratification model and its predictive value for cardiovascular disorders in the puerperium
Description: Identification of a risk stratification model for cardiovascular/hypertensive disorders in the puerperium using a panel of placental biochemical markers (sFlt-1 and PlGF: already used in pregnancy for prediction of preeclampsia), demographic, clinical and laboratory data.
Study: NCT06722872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laughter therapy
Description: Laughter therapy, developed by Dr. Madan Kataria in 1995, is a structured exercise program use of laughter and breathing exercises.Laughter therapy sessions begin with warm-up techniques, including clapping, singing, and stretching movements. These are followed by breathing exercises to prepare the lungs for laughter. After the breathing exercises, laughter is simulated using acting techniques. Shortly thereafter, the simulated laughter spreads from person to person through group dynamics, transforming into genuine laughter, which is then followed by a series of laughter exercises. A laughter therapy session may conclude with laughter meditation, during which participants allow natural laughter to flow freely, followed by guided relaxation exercises. To maximize the benefits of laughter's contagious nature, it is recommended that laughter therapy be conducted in groups. Each session varies depending on the target audience, typically lasting around 45 minutes.